20 Jan 2015

VBL Therapeutics Announces Ron Cohen and Philip Serlin Nominated to Board of Director

a-
A+
Customize font size:
Share:

TEL AVIV, Israel, Jan. 20, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company committed to the discovery, development and commercialization of first-in-class treatments for cancer and immune-inflammatory disease, today announced the nomination of industry veterans Ron Cohen, M.D., andPhilip Serlin, C.P.A. to stand for election to the Board of Directors at VBL's extraordinary general meeting of shareholders, scheduled for February 11, 2015. Both individuals currently are leaders of biotechnology companies publicly traded in the US: Dr. Cohen serves as the President and Chief Executive Officer of Acorda Therapeutics, Inc.(Nasdaq:ACOR) and Mr. Serlin is Chief Financial and Operating Officer of BioLineRx Ltd.(Nasdaq:BLRX).

"I am pleased to welcome both Ron and Phil to the proposed slate of directors, which represents a vote of confidence in VBL and our strong and innovative therapeutic pipeline," said Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics. "The depth of industry experience represented by these nominees will be invaluable as we continue to advance our clinical development pipeline. Their wide range of expertise, which includes research and development, commercial operations and financial accounting for publicly traded U.S. and Israeli companies, will be critical to VBL and we look forward to their contributions to the Company's continued success."

Bennett Shapiro, M.D., Chairman of the Board of Directors at VBL, said, "We are enthusiastic about working with Ron and Phil to develop VBL further during this important year as we expect key data in both our cancer and inflammation programs."

In addition to his position at Acorda, Dr. Cohen is a member of the Executive Committee and Vice Chair of the Health Section of the Biotechnology Industry Organization (BIO), and serves on the Board of Directors of Dyax Corp (Nasdaq:DYAX). He previously served as the Director and Chairman of the New York Biotechnology Association, and also serves as a member of the Columbia-Presbyterian Health Sciences Advisory Council. Dr. Cohen received his M.D. from Columbia University's College of Physician & Surgeons, and his B.A. in psychology, with honors, from Princeton. He completed his residency in Internal Medicine at the University of Virginia Medical Center and is Board Certified in Internal Medicine.

Prior to joining BioLineRx in 2009, Mr. Serlin was the Chief Financial Officer and Chief Operating Officer of Kayote Networks Ltd., and before that, he served as the Chief Financial Officer of Tescom Software Systems Testing Ltd. Mr. Serlin has also held senior positions at Chiaro Networks Ltd. and at Deloitte, where he headed the SEC and U.S. Accounting Department at the National Office in Tel Aviv, as well as at the SECheadquarters in Washington, D.C. He currently serves as a Director of Kitov Pharmaceuticals (TASE:KTOV). Mr. Serlin is a C.P.A. and holds a master's degree in Economics and Public Policy from The George Washington University and a B.Sc. in accounting from Yeshiva University.